Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Working Capital Changes (2016 - 2025)

Ironwood Pharmaceuticals' Other Working Capital Changes history spans 16 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 223.77% year-over-year to $1.3 million; the TTM value through Dec 2025 reached -$447000.0, down 402.25%, while the annual FY2025 figure was -$447000.0, 402.25% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was $1.3 million at Ironwood Pharmaceuticals, up from -$2.2 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $3.7 million in Q1 2023 and bottomed at -$4.6 million in Q2 2023.
  • The 5-year median for Other Working Capital Changes is -$512500.0 (2023), against an average of -$253950.0.
  • The largest annual shift saw Other Working Capital Changes tumbled 2733.87% in 2021 before it soared 7022.64% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.6 million in 2021, then dropped by 10.84% to -$1.8 million in 2022, then surged by 71.49% to -$516000.0 in 2023, then plummeted by 105.43% to -$1.1 million in 2024, then skyrocketed by 223.77% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Other Working Capital Changes are $1.3 million (Q4 2025), -$2.2 million (Q3 2025), and $1.0 million (Q2 2025).